



ASX ANNOUNCEMENT

19 June 2015

## **dorsaVi's US reimbursement strategy steps forward with CPT coding for ViMove and ViPerform**

**Melbourne, Australia** – Medical device company dorsaVi Ltd (ASX: DVL) today announced that an independent clinical research and reimbursement institute has determined that existing CPT codes can be used with dorsaVi's industry leading wearable sensor technology, ViMove and ViPerform in the US. CPT™ codes or Current Procedural Terminology Codes are numeric codes that enable healthcare providers to describe or report work performed under private and public insurance programs.

The Regulatory & Clinical Research Institute (RCRI) in Minneapolis, Minnesota reviewed applicability of CPT code sets to dorsaVi's ViMove and ViPerform products. Based on RCRI research, CPT code 97750, which is used to report a physical performance test or measurement, aligns with the activities performed when dorsaVi sensors and software are used to measure movement. The US Medicare national average clinician payment is US\$33.42 for each fifteen-minute block of services and a corresponding written report. Multiple units of the code can be billed in a single patient encounter provided documentation supports time spent directly with the patient.

Low back injuries have been increasingly recognised as a leading cause of disability around the world and a significant driver of healthcare costs. The ability to accurately and efficiently measure, report and assess human movement is critical to improving care and outcomes for patients with low back conditions. Estimates state that \$194 billion dollars are spent on the treatment of spinal conditions in the US every year.

"The US clinical market represents a massive opportunity for dorsaVi and clearing the path to rebate coding, coverage and payment will be substantial in advancing broader adoption of our clinically proven technology," said dorsaVi CEO Andrew Ronchi.

"We are committed to ensuring that patients have access to technology that we believe can significantly improve their lives and reduce health care expenditure."

dorsaVi wearable sensors allow clinicians, companies and elite sporting clubs to objectively measure and easily interpret data relating to human movement.

Patients who are candidates for an assessment by dorsaVi's ViMove or ViPerform system reflect the general patient population moving through typical orthopedic, physical therapy and occupational therapy care facilities. RCRI reimbursement experts determined that CPT code 97750 "may be added to the standard coding for the visit when the ViMove system is used. These codes may be used regardless of the actual assessment results."

In May, dorsaVi received expanded labelling for its 510(k) cleared ViMove product that is used to accurately assess movement and muscle activity in the low back and pelvis, manage treatment options, and guide recovery.

Determining applicability of this initial CPT code is the first step of a multistep reimbursement strategy for dorsaVi. The company expects to qualify for additional codes as new product capabilities, currently available in other geographies, are cleared for use in the US.

“This is an important milestone in broadening access to our technology,” said dorsaVi US President, John Kowalczyk. “Access to reimbursement is a significant barrier to the adoption of emerging health technologies. The CPT code evaluation findings from RCRI and the expanded labelling from the FDA will lead to more patients gaining access to our technology and help us fulfil our mission of inspiring the world to move well.”

The code noted here is a recommendation only, and reflect RCRI’s understanding of the identified sources, as prepared by its reimbursement consultants. This information should not be construed as authoritative. Codes and values are subject to frequent change without notice. The entity billing Medicare and/or third party payers is solely responsible for the accuracy of the codes assigned to the services and items in the medical record. Therefore, health care providers must use great care and validate coding requirements ascribed by payers with whom they work. RCRI assumes no responsibility for coding and cannot recommend codes for specific cases.

- ENDS -

**For more information or to arrange an interview, contact:**

**MEDIA**

Kellie Hanrick  
Buchan Consulting  
0413 681 346  
[khanrick@buchanwe.com.au](mailto:khanrick@buchanwe.com.au)

**INVESTOR**

Rebecca Wilson  
Buchan Consulting  
0417 382 391  
[rwilson@buchanwe.com.au](mailto:rwilson@buchanwe.com.au)

***About dorsaVi***

dorsaVi (ASX: DVL) is an ASX company focused on developing innovative motion analysis device technologies for use in elite sports, occupational health and safety, and clinical applications. dorsaVi believes its wearable sensor technology enables – for the first time – many aspects of detailed human movement and position to be accurately captured, quantified and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours.

Our technology has applications across three sectors:

- **OH&S:** We combine innovation, measurement and quality to reduce workplace incidents, costs, meet compliance and improve brand reputation. ViSafe enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to workplace design, equipment or methods based on objective evidence. ViSafe has been used by major corporations including Coles, Woolworths, Toll, Toyota, Orora (formerly Amcor), Crown and BHP Billiton. Australian Workplace Compliance delivers risk mitigation through compliance to OHS, Quality Management Systems, Company Policy and Process.
- **Clinical:** ViMove is transforming the management of patients by providing objective assessment, monitoring outside the clinic and immediate biofeedback. ViMove is currently used by medical and physiotherapy practices in Australia and the United Kingdom and is now available in the United States following FDA 510K clearance.
- **Elite Sports:** ViPerform is allowing coaches and medical teams managing elite athletes and teams to screen athletes and provide objective evidence for decisions on return to play, measure biomechanics and provide immediate biofeedback out on the field, tailor and track training programs and optimise technique and peak performance. ViPerform is being used by AFL and NRL clubs in Australia, clubs in the Barclays Premier League, Australian and Victorian Institutes of Sport, various Olympic teams and athletes internationally, and Cricket Australia.

Further information is available at [www.dorsavi.com](http://www.dorsavi.com).